Esperion Therapeutics Inc (ESPR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Esperion Therapeutics Inc (ESPR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH185154D
  • |
  • Pages: 44
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Esperion Therapeutics Inc (Esperion), a subsidiary of Pfizer Inc is a pharmaceutical company that develops and commercializes once-daily, oral and low-density lipoprotein cholesterol lowering therapies. The company develops oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate, Bempedoic acid is an ATP-citrate lyase inhibitor which is in Phase 3 clinical development that reduces elevated LDL-C levels in patients with hypercholesterolemia. The company also offers development of bempedoic acid in a fixed dose combination with ezetimibe, an LDL-C lowering therapy. Esperion is headquartered in Ann Arbor, Michigan, the US.

Esperion Therapeutics Inc (ESPR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note : Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Esperion Therapeutics Raises USD 33 Million In Venture Financing 11

Esperion Therapeutics Raises USD 1 Million In Venture Financing 13

Equity Offering 14

Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 14

Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 16

Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 18

Esperion Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 70 Million 20

Esperion Therapeutics Inc-Key Competitors 22

Esperion Therapeutics Inc-Key Employees 23

Esperion Therapeutics Inc-Locations And Subsidiaries 24

Head Office 24

Recent Developments 25

Financial Announcements 25

Aug 02, 2018: Esperion provides Bempedoic Acid franchise development program updates; reports second quarter 2018 financial results 25

May 02, 2018: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results 28

Feb 20, 2018: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 2017 Financial Results 29

Nov 07, 2017: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results 31

Aug 08, 2017: Esperion Reports Second Quarter 2017 Financial Results 33

May 04, 2017: Esperion Reports First Quarter 2017 Financial Results 34

May 04, 2017: Esperion Therapeutics Q1 net loss up 35

Feb 22, 2017: Esperion Reports Fourth Quarter and Full Year 2016 Financial Results 36

Corporate Communications 37

Aug 11, 2017: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 37

Legal and Regulatory 39

May 10, 2018: Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Esperion Therapeutics 39

May 07, 2018: Pomerantz Law Firm Announces the Filing of a Class Action against Esperion Therapeutics and Certain Officers-ESPR 40

Product Approvals 41

Jun 26, 2017: Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe 41

Clinical Trials 42

Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill 42

Aug 08, 2017: Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin 43

Appendix 44

Methodology 44

About GlobalData 44

Contact Us 44

Disclaimer 44

List of Figures

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Esperion Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Esperion Therapeutics Raises USD 33 Million In Venture Financing 11

Esperion Therapeutics Raises USD 1 Million In Venture Financing 13

Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 14

Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 16

Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 18

Esperion Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For IPO For USD 70 Million 20

Esperion Therapeutics Inc, Key Competitors 22

Esperion Therapeutics Inc, Key Employees 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Esperion Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 18043
Site License
USD 500 INR 36085
Corporate User License
USD 750 INR 54128

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com